Originally Posted by
MAC
Hi Snapiti,
Cxbladder(detect) would be applied first, if the patient did not test positive, then the clinician then has an option of applying a cxbladder(triage) test. The clinician may wish to do this if the patient is in a high risk category, eg: an ex-smoker with a family history of cancer.
It's difficult to assess the market for cxbladder(triage), I've been brooding on this for a few weeks now. Up to 3 million patients present with haematuria each year and a certain percentage of these will be in a high risk category, between 2 to 4% (depending on source) will have bladder cancer.
Ultimately, clinicians over time, years perhaps, will decide what percentage of patients to cxbladder(triage) test for confirmation and for the patients peace of mind, price point is important also if different from cxbladder(detect).
Although, if both a first stage cxbladder(detect) test and a cxbladder(triage) test can be performed from the same initial patient urine sample, then Pacific Edge may be able to market cxbladder(triage) as a priced option for haematuria screening. could be quite a good market in itself.
Hopefully we all get more detailed information from Pacific Edge soon.
regards, Mac